The laboratory conducting analysis of the DBS shall provide such analysis which includes, but is not limited to the following disorders:

1. (a) Phenylketonuria (PKU);
2. (b) Maple syrup urine disease (MSUD);
3. (c) Homocystinuria (HCY);
4. (d) Galactosemia (GALT);
5. (e) Congenital hypothyroidism;
6. (f) Toxoplasmosis;
7. (g) Hemoglobinopathies;
8. (h) Biotinidase deficiency (BIOT);
9. (i) Congenital adrenal hyperplasia (CAH);
10. (j) Medium chain acyl CoA dehydrogenase deficiency (MCAD);
11. (k) Cystic fibrosis (CF);
12. (l) Argininosuccinic aciduria (ASA);
13. (m) Argininemia (ARG);
14. (n) Carnitine uptake defect (CUD);
15. (o) Carnitine palmitoyltransferase II deficiency (CPTII);
16. (p) Citrullinemia I, (ASA synthetase def) (CIT);
17. (q) Cobalamin A,B (Cbl A,B);
18. (r) Glutaric aciduria type I (GAI);
19. (s) 3-hydroxy-3-methylglutaryl-CoA Lysase deficiency (HMG);
20. (t) Hyperornithinemia hyperammoninemia, homocitrullinemia syndrome (HHH);
21. (u) Isovaleric acidemia (IVA);
22. (v) Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHAD);
23. (w) 3-Methylcrotonyl-CoA carboxylase deficiency (3MCC);
24. (x) Methylmalonic acidemia (MUT);
25. (y) Mitochondrial acetoacetyl-CoA thiolase deficiency (BKT);
26. (z) Multiple acyl-CoA dehydrogenase deficiency (GA2);
27. (aa) Multiple carboxylase deficiency (MCD);
28. (ab) Propionic acidemia (PROP);
29. (ac) Severe combined immunodeficiency disorder (SCID);
30. (ad) Trifunctional protein deficiency (TFP);
31. (ae) Tyrosinemia;
32. (af) Very long chain acyl-CoA dehydrogenase deficiency (VLCAD);
33. (ag) Spinal muscular atrophy (SMA);
34. (ah) Mucopolysaccharidosis Type 1 (MPS1);
35. (ai) X-Linked Adrenoleukodystrophy (X-ALD); and
36. (aj) Pompe Disease (POMPE).

Source. #8529, eff 12-23-05; ss by #8875, eff 4-25-07; ss by #9725, eff 7-1-10; ss by #12632, eff 9-28-18; ss by #13530, eff 1-25-23